82 citations,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
41 citations,
December 2015 in “JAMA Dermatology” Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
39 citations,
April 2016 in “Case Reports in Dermatology” Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
37 citations,
January 2016 in “Drug design, development and therapy” Tofacitinib citrate is effective for moderate-to-severe chronic plaque psoriasis but has safety concerns at higher doses.
30 citations,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
26 citations,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
26 citations,
October 2016 in “American journal of clinical dermatology” New treatments like JAK inhibitors show promise for reversing alopecia areata.
24 citations,
June 2016 in “Acta dermato-venereologica” Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.
20 citations,
January 2017 in “Actas Dermo-Sifiliográficas” Recent advances in hair loss treatments show significant progress.
16 citations,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
9 citations,
August 2018 in “JAAD Case Reports” Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
9 citations,
December 2017 in “The Journal of Allergy and Clinical Immunology” New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.
2 citations,
March 2015 in “Expert opinion on orphan drugs” New treatments for hair loss show promise but need more research to confirm safety and effectiveness.
1 citations,
July 2018 in “Elsevier eBooks” Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
September 2023 in “Frontiers in medicine” The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
June 2023 in “Dermatology and therapy” Doctors in the Middle East need better treatments and more knowledge about new therapies for hair loss condition Alopecia Areata.
November 2020 in “Dubai medical journal” Tofacitinib may effectively regrow hair in alopecia totalis patients.
January 2016 in “Springer eBooks” Alopecia Areata is an unpredictable autoimmune hair loss condition with limited and variable treatment effectiveness.
8 citations,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
7 citations,
March 2017 in “Actas Dermo-Sifiliográficas” Several new treatments for different types of hair loss show promise in improving patient quality of life.
2 citations,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
October 2023 in “Frontiers in Medicine” Dupilumab helped a 4-year-old grow hair back after another treatment failed.
4 citations,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
2 citations,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
50 citations,
May 2021 in “Frontiers in immunology” Certain immune cells contribute to skin autoimmune diseases, and some treatments can reverse hair loss in these conditions.
48 citations,
April 2021 in “Journal of the American Academy of Dermatology” Topical corticosteroids are the best initial treatment for children's alopecia areata.
25 citations,
December 2017 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings” Targeted cytokine treatments may help with alopecia areata, but more research is needed.
22 citations,
September 2017 in “Skin appendage disorders” Ruxolitinib helped a man regrow his beard after years of hair loss.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
1 citations,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.